Tafenoquine plus DHA-Piperaquine — Competitive Intelligence Brief

Tafenoquine plus DHA-Piperaquine (Tafenoquine plus DHA-Piperaquine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Plasmodium hypnozoites (tafenoquine); Plasmodium blood-stage parasites (DHA-piperaquine) Infectious Disease Small molecule

Target snapshot

Tafenoquine plus DHA-Piperaquine (Tafenoquine plus DHA-Piperaquine) — Menzies School of Health Research. This combination uses tafenoquine to eliminate dormant malaria parasites in the liver and piperaquine (in DHA-piperaquine) to kill active blood-stage parasites, providing both curative and preventive antimalarial activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tafenoquine plus DHA-Piperaquine TARGET	Tafenoquine plus DHA-Piperaquine	Menzies School of Health Research	marketed	Antimalarial combination	Plasmodium hypnozoites (tafenoquine); Plasmodium blood-stage parasites (DHA-piperaquine)
amodiaquine-artesunate versus amodiaquine	amodiaquine-artesunate versus amodiaquine	Charite University, Berlin, Germany	marketed	Antimalarial combination	Malaria parasite heme detoxification pathway; artemisinin-derived endoperoxide bridge
lumefantrine plus artemether	lumefantrine plus artemether	Centers for Disease Control and Prevention	marketed	Antimalarial combination therapy	Malaria parasite heme metabolism and hemozoin formation
Artemether-lumefantrine combination plus albendazole	Artemether-lumefantrine combination plus albendazole	Navrongo Health Research Centre, Ghana	marketed	Antimalarial combination with anthelmintic	Plasmodium falciparum (multiple mechanisms); Ascaris, Hookworm, Trichuris (tubulin)
chlorproguanil-dapsone plus artesunate	chlorproguanil-dapsone plus artesunate	Centers for Disease Control and Prevention	marketed	Antimalarial combination	Dihydrofolate reductase (chlorproguanil/dapsone); mitochondrial function (artesunate)
arthemether + lumefantrine	arthemether + lumefantrine	Sanofi	marketed	Antimalarial combination	Plasmodium falciparum heme detoxification pathway; artemisinin-derived endoperoxide bridge
Artemether, Lumefantrine Drug Combination	Artemether, Lumefantrine Drug Combination	University of Yaounde 1	marketed	Antimalarial combination	Plasmodium falciparum heme and mitochondrial function

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class